Acrylamide, a probable human carcinogen, is ubiquitously present in the human environment, with sources including heated starchy foods, coffee and cigarette smoke.
Introduction
Cancer can be caused by chemicals, complex mixtures, occupational exposures, physical agents, and biological agents, as well as lifestyle factors. Many human carcinogens show a number of characteristics that are shared among carcinogenic agents (1) . Different human carcinogens may exhibit a spectrum of these key characteristics, and operate through separate mechanisms to generate patterns of genetic alterations. Recognizable patterns of genetic alterations or mutational signatures characterize carcinogens that are genotoxic.
Recent work shows that these DNA sequence changes can be expressed in simple mathematical terms that enable mutational signatures to be extracted from thousands of cancer genome sequencing data sets (2) . Several of the over 30 identified mutational signatures have been attributed to specific external exposures or endogenous factors through epidemiological and experimental studies (2) . However, about 40% of the current signatures remain of unknown origin, and additional, thus far unrecognized, signatures are likely to be defined in rapidly accumulating cancer genome data. Well-controlled experimental exposure systems can thus help identify the underlying causes of known orphan mutational signatures as well as define new patterns generated by candidate carcinogens (reviewed in (3, 4) ).
Various diet-related exposures contribute to the human cancer burden. Examples include contaminants in food or alternative medicines, such as aflatoxin B1 (AFB1) or aristolochic acid (AA). The mutagenicity of these compounds is well-documented; AFB1 induces predominantly C:G>A:T base substitutions and AA causes T:A>A:T transversions.
The characteristic mutations coupled with information on the preferred sequence contexts in which they are likely to arise allowed unequivocal association of exposure to AFB1 or AA with specific subtypes of hepatobiliary or urological cancers, respectively (5) (6) (7) (8) (9) (10) (11) (12) (13) .
Among dietary compounds with carcinogenic potential, acrylamide is of special interest due to extensive human exposure. Important sources of exposure to acrylamide include tobacco smoke (14) , coffee (15) , and a broad spectrum of occupational settings (16) .
Dietary sources of acrylamide comprise carbohydrate-rich food products that have been subject to heating at high temperatures. This is due to Maillard reactions, which involve reducing sugars and the amino acid asparagine, present in potatoes and cereals (17) . There is sufficient evidence that acrylamide is carcinogenic in experimental animals (18, 19) and it has been classified as a probable carcinogen (Group 2A) by the International Agency for Research on Cancer in 1994 (16) . The association of dietary acrylamide exposure with renal, endometrial and ovarian cancers has been explored in recent epidemiological studies (20, 21) . However, accurate acrylamide exposure assessment in epidemiological studies based on questionnaires has been difficult, and more direct measures of molecular markers, such as hemoglobin adduct levels, may not yield conclusive findings on past exposures (22) (23) (24) (25) (26) (27) ). An improved understanding of its mechanism of action using well-controlled experimental systems is critical for understanding the potential carcinogenic risk associated with exposure.
Acrylamide undergoes oxidation by cytochrome P450, producing the reactive metabolite glycidamide that is highly efficient in DNA binding due to its electrophilic epoxide structure (28) (29) (30) . The Hras mutation load in neoplasms of mice exposed to acrylamide or glycidamide was found to be considerably higher in mice treated with glycidamide (31) . This finding is corroborated by a considerably higher mutation frequency in the cII reporter gene of Big Blue mouse embryonic fibroblasts treated with glycidamide in comparison to acrylamide (32, 33) . Mutation analysis in different experimental in vivo and in vitro models using reporter genes showed an increased association of acrylamide and glycidamide exposure with T:A>C:G transitions, as well as T:A>A:T and C:G>G:C transversion mutations (31) (32) (33) (34) (35) (36) , whereas glycidamide exposure was also characterized by C:G>A:T transversions (33) . However, these proposed acrylamide-and glycidamide-specific mutation patterns were based on limited mutation counts in reporter genes and thus do not reflect the complexity of genome-wide distributions and profiles. Based on the limited data available thus far, it is not possible to translate adequately the reported mutation types (T:A>C:G, T:A>A:T, C:G>G:C, C:G>A:T) to global alteration patterns.
The advent of massively parallel sequencing has created the opportunity to study a large number of mutations in a single sample, thus significantly enhancing the power of mutation analysis in experimental models and enabling reliable identification of specific sequence contexts for the induced alterations. Analogously to human cancer genome projects, genome-scale mutational signatures can be extracted from highly controlled carcinogen exposure experiments using mammalian cell and animal models coupled with advanced mathematical approaches (2, 3, 37, 38) .
Here we report the systematic assessment of acrylamide and glycidamide mutagenicity based on DNA adduct formation and mutation profile analysis using massively parallel sequencing in a cell model amenable to the analysis of carcinogen-induced mutation patterns and their impact on the resulting cell phenotype (3, (37) (38) (39) . We identify a specific and robust mutational signature attributable to glycidamide, and by computationally interrogating human cancer genome-wide mutation data, we characterize glycidamide signature-positive tumors, thereby highlighting a potential contribution of acrylamide/glycidamide exposure to carcinogenesis in humans.
Materials and methods

Source and authentication of primary cells
Primary Human-p53 knock-in mouse embryonic fibroblasts (Hupki MEFs) were isolated from 13.5-day old Trp53 tm/Holl mouse embryos from the Central Animal Laboratory of the Deutsches Krebsforschungszentrum, Heidelberg, as described previously (40) . The mice had been tested for Specific Pathogen-Free (SPF) status. The derived primary cells were genotyped for the human TP53 codon 72 polymorphism (Table 1) to authenticate the embryo of origin. Cells from three different embryos (E210, E213 and E214) were used for the exposure experiments (Table 1 ). All subsequent cell cultures were routinely tested at all stages for the absence of mycoplasma.
Cell culture, exposure and immortalization
The primary MEF cells were expanded in Advanced DMEM supplemented with 15% fetal calf serum, 1% penicillin/streptomycin, 1% pyruvate, 1% glutamine, and 0.1% β-mercaptoethanol. The cells were then seeded in six-well plates and, at passage 2, exposed for 24
hours to acrylamide (A4058, Sigma), glycidamide (04704, Sigma), or vehicle (PBS).
Acrylamide exposure was carried out in the absence or presence of 2% human S9 fraction (Life Technologies) complemented with NADPH (Sigma). Exposed and control primary cells were cultivated until they bypassed senescence and immortalized clonal cell populations could be isolated (41) . The human mammary epithelial cell (HMEC) cultures utilized in this study for whole-genome sequencing (WGS) were generated from benzo[a]pyrene (B[a]P) exposed HMEC described previously (42, 43) .
MTT assay for cell metabolic activity and viability
Cells were seeded in 96-well plates and treated as indicated. Cell viability was measured 48 hours after treatment cessation using CellTiter 96® Aqueous One solution Cell Proliferation Assay (Promega). Plates were incubated for 4 hours at 37°C and absorbance was measured at 492 nm using the APOLLO 11 LB913 plate reader. The MTT assay was performed in triplicates for each experimental condition.
H2Ax Immunofluorescence
Immunofluorescence staining was carried out using an antibody specific for Ser139- Resulting sequences were analyzed using the CodonCode Aligner software.
Library preparation and whole-exome sequencing (WES)
Library preparation was carried out using the Kapa Hyper Plus library preparation kit (Kapa Biosystems) according the manufacturer's instructions. Exome capture was performed using the SureSelect XT Mouse All Exon Kit (Agilent Technologies). Eighteen exome-captured libraries were sequenced in the paired-end 150 base-pair run mode using the Illumina HiSeq4000 sequencer.
Processing of WES data
Fastq files were analyzed for data amount and quality using FastQC (0.11.3) and were processed with an in-house pipeline for adapter trimming and alignment to the mm10 genome (release GRCm38). Table S1 -not available in the preprint version), the list of identified MuTect SBS variants (Suppl . Table S2 -not available in the preprint version) and indels (Suppl . Table S3 -not available in the preprint version). We defined a 'pure' experimental C>N benzo[a]pyrene signature by WGS (using Illumina HiSeq4000 by Genewiz, NJ, USA) of finite lifespan post-stasis clones derived from primary human mammary epithelial cells (HMEC) treated with B[a]P as previously described (42, 43, 51) . The read alignment to NCBI GRCh38 genome build, variant calling, filtering and annotation were consistent with the MutSpec pipeline described above (45) . Proportion matrices of the experimental GA-signature, the GA-signature normalized to the human genome trinucleotide frequency to allow for human PCAWG data screening, and the wholegenome B[a]P signature are available in Suppl. Table S4 (not accessible in the preprint version).
Bioinformatics and statistical analyses
Results
Acrylamide and glycidamide induce cytotoxic and genotoxic responses in Hupki MEFs
Upon exposure of primary Hupki MEFs to a range of concentrations of acrylamide (ACR) (in the absence or presence of the S9 fraction) and its metabolite, glycidamide (GA), we observed a dose-dependent cytotoxic effect on the cells for either compound (Fig. 1A ). This analysis informed the selection of two conditions for the ACR exposure to be used in the subsequent exposure/immortalization experiments, 10 mM ACR for 24 hours in the absence of human S9 fraction, and 5 mM ACR for 24 hours in the presence of S9 fraction, which elicited 50% (range 30-70%) decrease in cell viability. The IC50 condition for GA was used for subsequent mutagenesis analysis, corresponding to a 24-hour treatment with 3 mM of the compound. The genotoxic effects of either ACR or GA manifested by a marked increase in γH2Ax staining in the exposed cell populations, in comparison to the mock-treated control cells (Fig. 1B) .
Immortalized MEF cells accumulate TP53 mutations following acrylamide or glycidamide treatment
Primary MEF cultures from three different embryos (Prim_1, Prim_2, and Prim_3) were exposed to ACR or GA using the established conditions and multiple immortalized clones were derived. MEF senescence and immortalization phases were evident from the growth curves generated for each culture (Suppl. Fig. S2 ). Subsequently, the clones derived from ACR exposure (ACR clones) and GA exposure (GA clones) and spontaneous immortalization (Spont), were pre-screened for TP53 mutations by Sanger sequencing, to assess the mutagenic process prior to exome-scale analysis. In the context of ACR treatment, clones obtained from the Prim_2 MEFs that were heterozygous for the polymorphic site in codon 72 showed a loss of heterozygosity involving a loss of the proline allele in the ACR_1 clone whereas the arginine allele was lost in ACR_2, giving rise to a hemizygous clone (Table 1) . No TP53 mutations were observed in any of the three Spont clones, whereas 3 out of 7 ACR clones and 1 of 5 GA clones carried non-synonymous TP53 mutations ( Table 1 ). The detected mutations indicated specific selection for mutations in the TP53 gene during cell immortalization and confirmed the clonal nature of MEF immortalization.
Analysis of mutation spectra
Whole-exome sequencing of all spontaneously immortalized and exposed clones and Table S1 and S2 -not available in the preprint version). This finding suggests markedly stronger mutagenic properties of GA in the MEFs. To estimate the extent of sequencing-related damage in our samples, we determined the GIV score of each sample as described in Materials and Methods and in (52) . No detectable damage for any of the mutation types was observed in our dataset (data not shown). The ACR exposed samples exhibited an overall diffuse pattern across the six different SBS types (Suppl. Fig.   S3 ). The Spont clones showed an enrichment of C:G>G:C SBS in the 5'-GCC-3' context, which was also present at varying levels in the exposed cultures. This particular mutation type appears to be related to the culture conditions used for the immortalization assay, as its presence has previously been noted upon spontaneous as well as exposure-driven MEF immortalization (37) . No significant transcription strand bias was observed for any of the mutation classes in the Spont or ACR clones (Suppl. Fig. S4 ). In the five clones derived from the GA-treated primary MEF cultures, we observed an enrichment of acquired T:A>A:T and C:G>A:T transversions and T:A>C:G transitions (Suppl. Fig. S3B ), marked by significant transcription strand bias (Suppl. Fig. S4 ).
PCA performed on the resulting 6-class SBS spectra unambiguously separated the GA clones from the remaining experimental conditions (Fig. 2A) . The analysis of indels (listed in Suppl. Table S3 -not available in the preprint version) showed lower numbers of these alterations in the GA-associated clones compared to the ACR or Spont clones (Fig.   2B ). This suggests that a higher accumulation of SBS may selectively promote the senescence bypass and selection of the GA clones, with a decreased functional contribution of indels, while an inverse scenario is plausible in case of the Spont and ACR clones, reminiscent of a previous report based on the Big Blue mouse embryonic fibroblasts and cII transgene (53) .
Variant allele frequency analysis
Variant allele frequency (VAF) analysis was carried out for GA clones. Overall, a significant proportion of acquired mutations was present at allelic frequencies between 25-75% (Suppl. 
Mutational signature analysis
Using NMF, we extracted the mutational signatures from all the MEF clones. Using computed statistics for estimating the number of signatures, three signatures were identified as an optimal number, with signatures A and C enriched in the Spont and ACR clones, and signature B selectively enriched in the GA clones (Fig. 2C,D) . Reconstruction of the observed mutation spectra supports the robustness of the signature analysis with strong
Pearson's correlation and cosine similarity in GA-derived clones (Fig. 2D) . In signature C and also to a lesser extent in signatures A and B, we observed an admixture of a pattern identical to the orphan COSMIC signature 17 (T:A>G:C in a 5'-NTT-3' trinucleotide context), described in various human cancers (most notably esophageal adenocarcinoma), but also seen in aflatoxin B1-driven mouse liver cancers (11), as well as primary MEF-derived clones (37, 38) . In in vitro contexts, this signature has been linked to cell culture conditions and associated oxidative stress (54, 55) . To refine further the obtained experimental signatures,
we developed a signature 'baiting' approach that combined the MEF clones data with signature 17-rich data from esophageal adenocarcinomas from the ICGC ESAD-UK study for new NMF analysis (56) . This resulted in considerable reduction (average = 47%, median = 48%) of the signature 17-specific most prominent T>G peaks and a more refined pattern for signature B, associated primarily with GA treatment (Fig. 3A and Suppl. Fig. S7 ). This putative GA signature retains the predominant enrichment for the T:A>A:T transversions and T:A>C:G transitions in the 5'-CTG-3' and 5'-CTT-3' trinucleotide contexts, and the C:G>A:T component. Moreover, these mutation types were marked by significant transcription strand bias ( Fig. 3B and Suppl. Fig. S4 ), exhibiting higher accumulation of mutations on the nontranscribed strand consistent with the decreased efficiency of the transcription-coupled nucleotide excision repair due to adduct formation.
DNA adduct analysis
Following metabolic activation, acrylamide induces well-characterized glycidamide DNA adducts at the N7-and N3-positions of guanine and adenine, respectively. LC-MS/MS-based adduct quantification revealed the absence of these adducts in the spontaneously immortalized control samples as well as in MEFs exposed to acrylamide in the absence of S9 fraction (levels below the limit of detection). This suggests the lack of CYP2E1 activity, which is required for the metabolism of acrylamide to glycidamide, in the MEFs. Upon addition of human S9 fraction, N7-GA-Gua levels increased to 11adducts/10 8 nucleotides,
suggesting limited metabolic activation of acrylamide due to the presence of enzymatic activity in the S9 fraction ( Fig. 3C and Suppl. Fig. S8 ). Glycidamide-exposed cells exhibited significantly increased DNA adduct levels, with both N7-GA-Gua and N3-GA-Ade observed at very high average levels, 49 000 adducts/10 8 nucleotides and 350 adducts/10 8 nucleotides, respectively, after subtracting the trace amount of contamination from the internal standard (Fig. 3C and Suppl. Fig. S8 ).
Comparison of the glycidamide signature to known signatures characterized by prominent T:A>A:T profiles
We next performed cosine similarity analysis of the putative GA signature and all known T:A>A:T-rich signatures extracted from primary cancers as well as experimental systems (Fig. 3D and Suppl. Fig. S9 ). The best match was 84% pattern similarity with COSMIC signature 25 (derived from four Hodgkin lymphoma cell lines) (Fig. 3D) . However, unlike the GA signature, COSMIC signature 25 exhibits strand bias for only T:A>A:T mutations and no transcription strand bias for the T:A>C:G mutations. Thus, the mutation patterns and strand bias on all three main mutation types generated by GA treatment (Fig. 3A,B ) appear specific and novel.
Glycidamide signature screening in human tumor data from the ICGC PCAWG
The initial mSigAct test performed on PCAWG data from lung and liver tumors indicated a marked presence of the GA signature. This observation was in keeping with the presence of acrylamide in tobacco smoke and was further corroborated by a cosine similarity of 94% between the adenine (T>N) components of COSMIC signature 4 (tobacco smoking) and the GA signature (Fig. 4A) . We thus hypothesized that COSMIC signature 4 reflects coexposure to B[a]P (generating C>N/guanine mutations with transcription strand bias) and to GA (generating T>N/adenine mutations with transcription strand bias) (Fig. 4A,B) . To provide further experimental evidence, we generated a 'pure' B[a]P mutational signature by whole-genome sequencing of cell clones derived from B[a]P-exposed normal human mammary epithelial cells (HMEC). This yielded a robust signature characterized by predominant strand biased guanine (mainly C>A) mutation levels and negligibly mutated adenines (T>N) (Fig. 4A,B) . Next, we used mSigAct to interrogate the PCAWG tumor Table S5 -not available in the preprint version).
Discussion
In this study we report the identification of an exome-wide mutational signature for In concordance with its in vivo carcinogenicity in rodents (16, 19, 31, 57) , our findings in the established MEF carcinogen exposure and immortalization system suggest that characteristic mutagenic effects may play a role during acrylamide/glycidamide-driven tumor development. In contrast to glycidamide, acrylamide exposure led neither to an increased number of SBS nor did it induce characteristic mutation types in the MEF exposure system.
Despite the absence of a mutagenic effect of acrylamide in our experiments, acrylamide and glycidamide exposures induce an almost identical set of tumors in both mice and rats, providing a substantial argument for a glycidamide-mediated tumorigenic effect of acrylamide (19) . This is further supported by mechanistic studies showing that lung tissue from mice exposed to acrylamide and glycidamide displays comparable DNA adduct patterns as well as similar mutation frequencies in the cII transgene (36). Similar observations had been made in the context of in vitro mutagenicity of acrylamide in human and mouse cells, suggesting the key role for epoxide metabolite glycidamide to form premutagenic DNA adducts (33) .
As shown by our adduct analysis, acrylamide is not efficiently metabolized by MEFs.
This finding is in keeping with the results from previous animal carcinogenicity studies. In fact, glycidamide induces hepatocellular carcinomas in neonatal B6C3F1 mice, whereas administration of acrylamide does not increase the tumor incidence. This has been attributed to the inability of neonatal mice to efficiently metabolize acrylamide (31) . Moreover, in contrast to acrylamide treatment, glycidamide induces tumors of the small intestine in a dose-dependent manner upon perinatal exposure (57) and similar observations were made for glycidamide mutagenicity in vitro (33) . We compensated for the lack of proper acrylamide metabolic activation by the addition of human S9 fraction, and the assessment of DNA adducts indeed suggests acrylamide metabolic activation upon addition of S9. However, the adduct levels are substantially lower compared to glycidamide exposure, which may account for the observed differences in mutagenicity. Interestingly, a consistent minor contribution of the glycidamide mutational signature was detected in the majority of ACR clones, whereas it was absent in the Spont clones. This raises the possibility that partial metabolic activation of acrylamide in the MEF system resulted in low levels of glycidamide. However, a clear mutational signature in the employed experimental setting was achieved only by exposing the cells directly to glycidamide.
Single reporter gene studies had previously linked acrylamide and glycidamide exposure to multiple different mutation types. Thanks to the larger number of mutations captured by exome sequencing, we were able to attribute to the glycidamide exposure a particular mutational signature characterized by strand-biased C:G>A:T and T:A>A:T transversions, and T:A>C:A transitions towards the non-transcribed strand suggesting a formation of DNA-adducts. The presence of N7-GA-Gua and N3-GA-Ade, two wellcharacterized glycidamide DNA adducts originating from the metabolic conversion of acrylamide (30, 44, 53) , shows a remarkable relationship between DNA adduct profiles and the putative mutational signature of glycidamide. N3-GA-Ade and N7-GA-Gua are depurinating adducts. They can result in apurinic/apyrimidinic sites, which, during replication, induce the mis-incorporation of deoxyadenine, leading to the observed T:A>A:T and C:G>A:T transversions of the glycidamide signature, respectively. The third mutation type specifically enriched in the glycidamide signature, T:A>C:G transitions, has been ascribed to the N1-GA-Ade adduct, a miscoding adduct and the most commonly identified adenine adduct in vitro (35, 44, 53, 58) . Levels of the guanine adduct were especially high in the exposed MEF cells, whereas the associated C:G>A:T transversions in the resulting postsenescence clones were less represented. This could reflect differences in DNA repair efficiency concerning individual GA-DNA adduct species, or the fact that the resulting clones are derived from single cells whereas the GA-DNA adducts were measured on average in the bulk primary cell population. A mechanism of negative selection of cells with high N7-GA-Gua adduct burden is also plausible.
We observed consistent presence of COSMIC signature 17 in the data generated from the untreated and treated MEF clones. The etiology of signature 17 remains unknown.
While some candidate causal factors have been proposed in esophageal adenocarcinoma and gastric cancers (e.g., inflammatory conditions due to acid reflux, H. pylori) (56) and in cultured mouse cell systems (54, 55) , further studies are required to establish why signature 17 tends to arise in vitro in immortalized clones derived from mouse embryonic fibroblasts as observed in our study and also previous work (38) .
Genome-scale sequencing of tumor tissues will be needed to verify, in vivo, the glycidamide mutational signature identified in this study. The established animal models (18, 19) of acrylamide-and glycidamide-mediated tumorigenesis provide a suitable starting point, and it would be interesting to compare mutational signatures derived from these models with the in vitro results. The identified glycidamide signature with its extended features of transcription strand bias for the major mutation types differs from the currently known COSMIC signatures (Fig. 3D) . In addition, we show that in the cancer genome sequencing data sets from the ICGC PCAWG effort, the putative glycidamide-mutational signature can be identified in a subset of tumors of the lung and liver (sites of possible acrylamide exposure due to tobacco smoking), based on combining experimentally derived signatures with sophisticated computational signature reconstruction approaches (Fig. 4) . 
